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Abstract
Background: This case represents the first report of malignant primary cardiac tumour in a patient with Lynch
Syndrome associated with MSH2 pathogenic variant.
Case presentation: A 57-year-old woman with previous ovarian cystadenocarcinoma was admitted to the
emergency room for hematic pericardial effusion. Multimodal diagnostic imaging revealed two solid pericardial
vascularized masses. After pericardiectomy, the final histological diagnosis was poorly differentiated pleomorphic
sarcomatoid carcinoma. During follow-up she developed an ampulla of Vater adenocarcinoma. Genetic analysis
identified an MSH2 pathogenic variant.
Conclusion: This case contributes to expand the tumour spectrum of Lynch syndrome, suggesting that MSH2
pathogenic variants cause a more complex multi-tumour cancer syndrome than the classic Lynch Syndrome. In
MSH2 variant carriers, symptoms such as dyspnoea and chest discomfort might alert for rare tumours and a
focused cardiac evaluation should be considered.
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Background
Lynch syndrome (LS) is an autosomal dominant disorder
caused by a germline mutation in one of the DNA mis-
match repair (MMR) genes (MLH1, MSH2, MSH6,
PMS2) or by a loss of expression of MSH2 due to dele-
tion in the EPCAM gene [1]. It is estimated that 1 in
279 people carry mutations in DNA mismatch repair
genes [2]. Patients with MMR gene mutations have a
significantly increased risk for cancer [3, 4]; indeed, LS is
the most common inherited colorectal susceptibility syn-
drome, accounting for approximately 3% of newly
diagnosed cases of colorectal cancer and 3% of cases of
endometrial cancer [5]. Although the predominant ma-
lignancies are colorectal and endometrial cancer, a wide
variety of malignancies is reported, with sites including
ovary, upper urinary tract, stomach, small bowel, pan-
creas, biliary tract, skin, and brain [6]. However, to the
best of our knowledge, no reports have described the oc-
currence of primary cardiac tumours in LS patients.
Herein, we report a case of pleomorphic sarcomatoid
pericardial carcinoma in a LS patient.
Case presentation
A 57-year-old woman was admitted to our emergency
room for worsening dyspnoea. Her past medical history
included salpingo-ovariectomy for an ovarian cystadeno-
carcinoma in 1996 (15 years negative oncological follow-
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up). Unfortunately, histological details of this tumour
were unavailable.
At clinical examination the patient appeared sweaty,
with low blood pressure and turgor of jugular veins (JVP:
12 cmH2O). Transthoracic echocardiography (Fig. 1a)
showed ubiquitous pericardial effusion (max 22mm) with
initial signs of hemodynamic instability; pericardiocentesis
was thus performed with aspiration of 400 cc of hematic
fluid. The cytological examination for malignant neoplas-
tic cells was negative.
Laboratory findings revealed a normal blood cell
count, negative autoimmunity, microbiological and on-
cologic screening with the exception of CA-125: 247 U/
ml (related to pericardial effusion).
Chest-abdomen computed-tomography (CT) (Fig. 1b)
revealed a pericardial effusion at the right ventricle apex
with focal areas of intense enhancement, compatible
with ongoing bleeding. No liver, spleen, pancreas, ad-
renal and kidney lesions were observed.
Considering the echocardiographic stability of the peri-
cardial effusion, in contrast with the CT findings, a cardiac
magnetic-resonance (MR) (Fig. 1c) was performed show-
ing two contiguous oval formations, on the anterior peri-
cardial recess, both 12 × 15mm with fluid/suprafluid
content, thin walls and intense contrast impregnation.
The diagnostic work-up was completed by a 18F-
labelled 2-fluoro-2-deoxy-D-glucose Positron-Emission-
Tomography/Computed Tomography (18F-FDG PET/
CT) and a focal area of radiotracer hyper-accumulation
in the anterior pericardium recess (SUV max 12.6) was
identified (Fig. 1d).
Diagnostic suspicion therefore shifted to a vascularized
solid pericardial lesion, and the patient underwent pericar-
diectomy through a left sub-mammary mini-thoracotomy
approach.
The surgical specimen was a piece of pericardium
with a 4 × 2 cm polylobate mass, constituted by a
solid greyish tissue and a necrotic yellowish nodular
area (Fig. 2a-c). Histology revealed a malignant prolif-
eration of pleomorphic spindle and epithelioid cells,
some multinucleated, growing in solid nests and/or in
a storiform pattern. The neoplasia showed atypical
mitosis (3/10 mitotic index) and extensive necrotic
areas (> 50% of the tumour surface) (Fig. 2d-f). At
immunohistochemistry, neoplastic cells were diffusely
positive for vimentin and smooth-muscle actin and, in
multifocal areas, for cytokeratin7 (Fig. 2g-i). Table 1
summarizes the immunohistochemical results. Despite
some atypical aspects of the overall picture, histologic
and immunophenotypic findings indicated the final
Fig. 1 Diagnostic imaging. (A) Transthoracic echocardiograph showing ubiquitous pericardial effusion (max 22 mm) with initial signs of
hemodynamic instability. (B) CT scan showing pericardial effusion localized near the right ventricle apex with marked contrast enhancement. (C)
Cardiac MR showing two contiguous oval formations, on the anterior pericardial recess, (12 × 15mm) with fluid/suprafluid content, thin walls and
intense contrast impregnation. (D) 18F-FDG PET/CT showing a focal area of radiotracer hyperaccumulation at the anterior pericardium recess
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diagnosis of poorly differentiated pleomorphic sarco-
matoid carcinoma (pT1Nx M0).
Considering the radical nature of the surgery, the ab-
sence of further distant disease localizations, the low
proliferative index and the lack of scientific evidence that
an adjuvant medical treatment reduces the risk of dis-
ease recurrence, we started a programme of close
clinical-instrumental surveillance.
Cardiac-MR and 18F-FDG-PET/CT performed during
follow-up revealed no lesions either in the residual pericar-
dium or in the cardiac chambers until June 2018 when the
MR showed no relapse of cardiac disease but did reveal a
new hepatic lesion. 18F-FDG-PET/CT excluded hepatic in-
volvement but identified a focal area of radiotracer hyper-
accumulation in the duodenum (SUV max: 14.4). In order
to further characterize such lesion, an echoendoscopy was
performed showing a 25mm mass near Vater’s ampulla,
infiltrating biliary and pancreatic tracts. Histological ana-
lysis indicated an infiltrating adenocarcinoma.
The patient underwent pancreaticoduodenectomy and
histological examination confirmed the presence of
moderately differentiated ampulla of Vater adenocarcin-
oma with polypoid extension in the biliary tract and in
the duct of Wirsung; there was no involvement of the
lymph nodes and the surgical margins were neoplasia-
free (pT2N0M0, TNM stage IB).
The patient did not undergo chemotherapy treatment
due to the disease staging but continued with close clin-
ical and instrumental follow-up. Chest-abdomen-CT and
cardiac-MR performed during follow-up did not show
disease relapse either in the cardiac chambers and peri-
cardium or in the duodenum.
Fig. 2 Cardiac mass pathology. Macroscopic appearance of neoplastic mass within the pericardial specimen (A: white circle) and on transverse
cuts (B, arrow). The histology macrosection (C) shows infiltration of pericardial tissue by malignant proliferation (arrows) and an extensive area of
necrosis (asterisk). At higher magnification, pleomorphic spindle and epithelioid cells are evident (D-E: Haematoxylin-Eosin 100x) as are
multinucleated cells (F: Haematoxylin-Eosin 400x). Immunohistochemistry showing diffuse, strong immunostaining for vimentin (G: 200x) and
smooth muscle actin (H: 200x) and, in multifocal areas, for cytokeratin-7 (I: 200x)
Paolisso et al. BMC Cancer          (2020) 20:191 Page 3 of 6
Due to the very rare cardiac tumour histotype, a mo-
lecular characterization of the cardiac tumour (other tu-
mours tissues were unavailable) was performed by
FOUNDATIONONE®CDx, a commercially available Next
Generation Sequencing (NGS)-based analysis of hundreds
of cancer-related genes. Pericardial lesion analysis showed
mutations in five genes: CD79A (R131fs*61), SETD2
(F1132fs*22), MLH1 (N168fs*4), MSH2 (F58Ilefs*27),
TP53 (R175H), as well as a high tumour mutational bur-
den and an intermediate microsatellite status. In the
meantime, the patient was referred to our Cancer Genet-
ics Clinic for genetic counselling because of the personal
history of early onset multiple malignancies suggesting an
inherited cancer predisposition. Extended pedigree collec-
tion (Fig. 3) showed a history of uterine cancer in the
paternal grandmother and in two of her sisters, while two
paternal cousins were reported to have developed colorectal
cancer. Clinical cancer genetic testing (NGS-based 27-gene
panel) detected the germline pathogenic variant c.171_
172insATCCGGGTGA (p.F58Ilefs*27) of the MSH2 gene,
which was diagnostic for LS7. This made it possible to im-
plement a proper endoscopic surveillance programme for
the patient and to offer predictive genetic testing to
relatives. The daughter, who as a child had been treated for
Acute Lymphoblastic Leukemia, was proven to carry the
MSH2 variant as well. Targeted testing was then offered to
other family members and demonstrated that the variant
had been inherited from the father, who developed colorec-
tal cancer shortly after the genetic diagnosis in the proband
(at the age of 83), while was absent in the healthy 53-year-
old proband’s sister. Among the clinically relevant muta-
tions found in the tumour tissue, the MSH2 variant was the
same as detected by germline testing, while the MLH1 and
TP53 mutations were confirmed to be somatic by both the
germline panel test and targeted Sanger sequencing.
Discussion and conclusion
Primary cardiac tumour are uncommon, with an esti-
mated prevalence around 0.02–0.056%, among these the
prevalence of primary pericardial neoplasms ranges from
0.001 to 0.007% [7–9]. This is the first report of
malignant primary cardiac tumour in a patient with LS
associated with a MSH2 pathogenic variant. Among LS
patients, the majority of those developing extraintestinal
malignancies are MSH2 mutation carriers [10, 11]. Re-
cent studies have shown that LS patients may present
different neoplastic formations according to age, gender
and type of MMR defect [3, 4]. Furthermore, a worse
prognosis has emerged among the elderly [4].
Our case supports this evidence, since the patient did
not develop the predominant Lynch malignancies (colo-
rectal and endometrial cancer), while she did develop
rare LS manifestations (ovarian cancer, Vater papilla car-
cinoma) and the unusual cardiac tumour hereby de-
scribed. The case was further characterized throughout
tumour NGS analysis, leading to the identification of
additional somatic events, with a high mutation burden
which is consistent with the underlying DNA MMR de-
fect [12]. This comprehensive approach was essential for
a proper practical management of our patient. In fact,
the extraordinary rarity of the case together with the
personal history of cancer raised the suspicion of DNA
germline predisposition which ultimately led to genome
profiling in order to identify molecular alterations poten-
tially beneficial for diagnosis, treatment and follow-up.
MSH2 inactivation leads to MMR defects, MSI, and a
high mutational burden, which may have an important
implication in predicting response to immunotherapies
like pembrolizumab and nivolumab [13, 14] . In case of
non-operable disease recurrence or new non-operable
cancer, in addition to conventional chemotherapies, the
patient could have been a candidate to receive immuno-
therapy, currently widely used and effective in other
solid neoplasms such as melanoma, non-small cell lung
cancer and renal cell carcinoma [15]. Our clinical report
described a cardiac involvement in a patient with a gen-
etic mutation in MSH2 causative of LS. In this setting, it
Table 1 Immunohistochemistry results
Antibody Result
Vimentin diffuse, strong immunostaining
Smooth muscle actin diffuse, moderate immunostaining
Cytokeratin 7 multifocal, moderate immunostaining
Cytokeratin 5–6 focal, strong immunostaining
Cytokeratin 19 very focal, strong immunostaining
P53 diffuse, strong immunostaining
Myogenin negative
Desmin negative
Calretinin negative
Wide-spectrum cytokeratin negative
S100 protein negative
CD31 negative
CD34 negative
Factor VIII negative
Epithelial membrane antigen negative
SOX-1 negative
Mart1-MelanA negative
HMB-45 negative
CD45 negative
Synaptophysin negative
WT1 negative
PAX 8 negative
KBA negative
MDM2 negative
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was crucial to perform endoscopic surveillance of our
patient [16] and genetic analysis of her first-degree rela-
tives [17]. This case contributes to expand the tumour
spectrum of LS, suggesting that MSH2 pathogenic vari-
ants cause a more complex multi-tumour cancer syn-
drome than the classic form of LS. Therefore, in MSH2
variant carriers, the occurrence of symptoms such as
dyspnoea and chest discomfort should advise clinicians
to perform a focused cardiac evaluation by 2D-
echocardiogram as rare tumours might be detected.
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